Home ›
Leukemia Trials ›
NCT07783100
Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
Trial Details
NCT ID NCT07783100
Phase PHASE2
Sponsor The First Affiliated Hospital of Xiamen University
Status RECRUITING
Cancer Type Leukemia
Interventions venetoclax, chidamide, and chiglitazar sodium (VCC)
Locations (sample) Xiamen, Fujian, China|24.47979,118.08187
Key Eligibility Criteria
Histologically confirmed acute myeloid leukemia (AML) with relapsed or refractory disease, including: Refractory AML, defined as failure to achieve remission after at least one prior treatment; Relapsed AML, defined as ≥5% blasts in the bone marrow after a previous remission; AML arising from myelodysplastic syndrome (including CMML) or myeloproliferative neoplasms (secondary AML or therapy-related AML \[t-AML\]) is also…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →